Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 24.69 USD 1.94% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Wall Street
Price Targets

DNLI Price Targets Summary
Denali Therapeutics Inc

Wall Street analysts forecast DNLI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DNLI is 42.53 USD with a low forecast of 28.28 USD and a high forecast of 94.5 USD.

Lowest
Price Target
28.28 USD
15% Upside
Average
Price Target
42.53 USD
72% Upside
Highest
Price Target
94.5 USD
283% Upside

DNLI Last Price Targets
Denali Therapeutics Inc

The latest public price target was made on Nov 1, 2024 by Michael Yee from Jefferies , who expects DNLI stock to rise by 82% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Michael Yee
Jefferies
45 USD
Upside 82%
3 weeks ago
Nov 1, 2024
Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies
StreetInsider
Thomas Shrader
BTIG
35 USD
Upside 42%
1 month ago
Oct 14, 2024
BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
Tazeen Ahmad
Bank of America Securities
29 USD
Upside 17%
2 months ago
Sep 4, 2024
Denali Therapeutics price target raised to $29 from $25 at BofA
TheFly
Salveen Richter
Goldman Sachs
46 USD
Upside 86%
2 months ago
Sep 3, 2024
Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
Marank Mamtani
B.Riley Financial
33 USD
Upside 34%
2 months ago
Sep 3, 2024
B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
Paul Mattels
Stifel Nicolaus
22 USD
Downside 11%
2 months ago
Sep 3, 2024
Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
StreetInsider
Show More Price Targets
Show Less Price Targets
Michael Yee
Jefferies
Price Target 45 USD
Upside/Downside 82%
View Source
Thomas Shrader
BTIG
Price Target 35 USD
Upside/Downside 42%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 29 USD
Upside/Downside 17%
View Source
Salveen Richter
Goldman Sachs
Price Target 46 USD
Upside/Downside 86%
View Source
Marank Mamtani
B.Riley Financial
Price Target 33 USD
Upside/Downside 34%
View Source
Paul Mattels
Stifel Nicolaus
Price Target 22 USD
Upside/Downside 11%
View Source
Show More Price Targets
Show Less Price Targets
Denali Therapeutics Inc Competitors:
Price Targets
MCRB
Seres Therapeutics Inc
414% Upside
2256
Abbisko Cayman Ltd
171% Upside
PROB
Probi AB
39% Downside
086890
Isu Abxis Co Ltd
97% Upside
FLUO
Fluoguide AS
309% Upside
VRTX
Vertex Pharmaceuticals Inc
17% Upside
AGIO
Agios Pharmaceuticals Inc
1% Upside
BBIO
BridgeBio Pharma Inc
108% Upside

Revenue
Forecast

Revenue Estimate
Denali Therapeutics Inc

The compound annual growth rate of Denali Therapeutics Inc's revenue for the next 3 years is -19%.

N/A
Past Growth
-19%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Denali Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Denali Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DNLI's stock price target?
Price Target
42.53 USD

According to Wall Street analysts, the average 1-year price target for DNLI is 42.53 USD with a low forecast of 28.28 USD and a high forecast of 94.5 USD.

What is Denali Therapeutics Inc's Revenue forecast?
Projected CAGR
-19%

The compound annual growth rate of Denali Therapeutics Inc's revenue for the next 3 years is -19%.

Back to Top